SEMAGLUTIDE IN OBESITY AND EXERCISE MEDICINE: A REVIEW OF CLINICAL EVIDENCE, PERFORMANCE IMPLICATIONS, AND IMPLEMENTATION CHALLENGES
Authors:
- Aleksandra RomaniukARAleksandra Romaniuk
- Sofiya SalashSSSofiya Salash
- Artur KozaAKArtur Koza
- Anna KarczAKAnna Karcz
- Barbara PająkBPBarbara Pająk
- Hubert Bołdys-ŻegockiHBHubert Bołdys-Żegocki
- Jakub MajewskiJMJakub Majewski
- Maria KanieckaMKMaria Kaniecka
- Małgorzata DworniczakMDMałgorzata Dworniczak
- Oliwia WróblewskaOWOliwia Wróblewska
Open Access
- 30 June 2026
- journal article
- review article
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (2(50))
Abstract
Background. Obesity is a growing global public health issue. Semaglutide (Ozempic), a glucagon-like peptide-1 receptor agonist (GLP-1 RA), represents a breakthrough in obesity pharmacotherapy, with documented benefits in weight reduction, metabolic control, and cardiovascular risk reduction. Aim. To review key clinical evidence on semaglutide in obesity treatment, explain its mechanism of action, and discuss practical aspects of implementing semaglutide therapy in Poland, including accessibility and long-term use, with particular emphasis on integration with physical activity and rehabilitation. Material and methods. The article is based on a narrative synthesis of existing sources, including key clinical trials, meta-analyses, international recommendations, and Polish regulatory and reimbursement documents concerning semaglutide use in obesity. Conclusions. Semaglutide is an effective and innovative pharmacological option in obesity management, with additional potential benefits for physical activity tolerance and weight-related rehabilitation in both recreationally active and sedentary individuals. Optimal long-term outcomes require combining semaglutide therapy with comprehensive lifestyle interventions, particularly structured exercise programs, while addressing challenges of accessibility and long-term treatment in Poland.Keywords
This publication has 14 references indexed in Scilit:
- Tirzepatide as Compared with Semaglutide for the Treatment of ObesityNew England Journal of Medicine, 2025
- Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity SocietyThe American Journal of Clinical Nutrition, 2025
- Muscle matters: the effects of medically induced weight loss on skeletal muscleThe Lancet Diabetes & Endocrinology, 2024
- Reflections on the discovery GLP-1 as a satiety hormone: Implications for obesity therapy and future directionsEuropean Journal of Clinical Nutrition, 2024
- Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trialNature Medicine, 2024
- Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trialNature Medicine, 2022
- Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trialThe Lancet Diabetes & Endocrinology, 2021
- Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or ObesityJAMA, 2021
- Once-Weekly Semaglutide in Adults with Overweight or ObesityNew England Journal of Medicine, 2021
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 DiabetesNew England Journal of Medicine, 2016